RT Journal Article
SR Electronic
T1 Audio-Visual Stimulation Therapy for Chronic Neuropathic Pain: A Sham-Controlled Randomized Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.12.24311569
DO 10.1101/2024.08.12.24311569
A1 Tabacof, Laura
A1 Howard, Rebecca
A1 Bower, Jeffrey
A1 Breyman, Erica
A1 Dewil, Sophie
A1 Tosto-Mancuso, Jenna
A1 Hanbury, Richard
A1 Carmouche, Brandon
A1 Robberson, Mark
A1 Fry, Adam
A1 Putrino, David
YR 2024
UL http://medrxiv.org/content/early/2024/08/13/2024.08.12.24311569.abstract
AB Neuropathic Pain (NP) affects 10% of the general population, decreasing quality of life for millions of Americans and contributing to higher physical and mental health care costs. The most widely used treatments for NP involve medications that show limitations in efficacy and burdensome side effects. This randomized controlled trial explored the efficacy of a wearable Audio-Visual Stimulation neuromodulation device (Sana) as a novel intervention for chronic NP in 64 participants. Outcomes were assessed at baseline, after 8-weeks of daily use of the assigned Sana or Sham device, and after 4 weeks of discontinued use. For the main outcome (Neuropathic Pain Symptom Inventory total), there were statistically significant improvements in the Active arm that were greater than those in the Sham Arm at Week-14 (Mean Difference = 10.04, p = 0.01). Both groups showed significant improvements at the end of the treatment period (Week-10), and the Active arm maintained this improvement after an additional 4 weeks of non-use, while the Sham arm almost returned to baseline (Active Change = 13.26, p <=0.001 | Sham Change = 3.22, p = 0.214). Participants in the Active arm had significant decreases in use of anxiolytic, opiate, antidepressant, and anticonvulsant medications compared to the Sham arm. The study provides strong evidence supporting the efficacy of a novel AVS Device in generating durable improvements in NP, with superiority over Sham at 14 weeks. The Sana device may also reduce the reliance on pain medications and is a safe and easy to use treatment option for patients.Competing Interest StatementFunding for the study was provided by Sana Health, Inc. At the time of submission, Richard Hanbury holds the title of CEO of Sana Health, Inc, and Jeffrey Bower holds the title of VP of Analytics at Sana Health, Inc. The other authors have no conflicts of interest to declare.Clinical TrialNCT04280562Funding StatementFunding for the study was provided by Sana Health, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study procedures were approved by the Mount Sinais Program for Protection of Human Subjects 18-2282 and registered on a national clinical trials registry (ClinicalTrials.gov Identifier: NCT04280562 Remote Participation (Within USA) Trial of the AVS Device (named the Sana Device developed by Sana Health, Inc, CO, USA).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available from the authors upon reasonable request. Please contact jeff{at}sana.io for data inquiries.